THE WORLD’S FIRST SCALABLE THROUGH-TISSUE PERFUSION PLATFORM
Human Tissue, Alive at Scale
We broke the diffusion limit of engineered tissues.
By delivering controlled, capillary-scale flow throughout the tissue volume, we create dense, viable multi-mm³ human tissue models for long-duration drug testing and disease modelling beyond the practical limits of organoids and bioprinted tissues.
Our approach
We use permeable capillaries that are embedded in the tissue, just like blood vessels, to deliver oxygen, nutrients, and therapeutic compounds from the inside. Unlike organoids, Livegrid tissues are truly perfused, not simply bathed in medium.
From Flow-Around to Flow-Through
Reliable human-relevant tissue models remain a long-standing challenge
Patients and the global biopharmaceutical industry need better in vitro models that can reliably predict drug efficacy and toxicity and reproduce disease biology before clinical testing. Without such models, drug development will remain extremely expensive and lengthy and will continue to consume animal lives in the process.
While state-of-the-art methods such as organoids and organ-on-chip systems have advanced tissue and disease modelling far beyond conventional cell cultures, their complexity and human relevance are severely limited by small tissue size and an uneven supply of nutrients — a constraint resulting from a lack of functional vasculature, which would otherwise deliver nutrients evenly throughout the tissue.
Our approach removes the immediate need for biological vasculature by introducing a synthetic alternative: a precisely defined network of permeable capillaries. This provides:
Exceptional viability, size, and long-term culture times.
Nutrient-demanding tissues, such as brain or liver, maintain nearly 100% cell viability over months of culture, with a shorter differentiation timescale and greater maturity than conventional organoids.
Greater morphological and functional complexity.
Compared with organoids, our tissues demonstrate extensive morphological features, markers of mature phenotypes, and several-fold higher enzymatic activity than in organoids.
Shorter assay times
Large-scale Livegrid tissues provide high cell-to-medium ratios and higher analyte signal-to-noise ratios. This enables faster assay convergence, earlier PK time points, and sharper detection of low-abundance biomarkers.
Foundation for new approach methodologies (NAMs) and Defined Approach development.
Precisely defined transport across a dense 3D tissue volume enables controlled volumetric exposure of the tissue to oxygen, nutrients, and therapeutic compounds. This lays the foundation for developing regulatory-grade 3D assays and Defined Approaches for chemical hazard assessment and preclinical testing.
Current application areas
We are developing assays for studies that require sustained tissue function, controlled exposure, and repeated measurement over extended periods.
Hepatic clearance and PK
Long-duration liver models for low-clearance compounds, metabolite kinetics, and IVIVE/PBPK parameterisation.
Repeated-dose liver safety
Perfused liver tissues for drug-induced liver injury (DILI), cholestatic liability, and chronic toxicity studies with longitudinal readouts.
Neural function and disease
Perfused neural tissues for studies of neurotoxicity and epilepsy, with long-term electrophysiological readouts.
Who we work with
We work with pharma, biotech, CROs, academic groups, and technology partners interested in more predictive human in vitro models.
Livegrid is currently focused on platform validation, application development, and selected collaborations.
Contact us to discuss a pilot study, assay collaboration, or platform partnership.
Contact us